Randomised phase-III-study of the multi-kinase inhibitors Sorafenib (BAY 43-9006) for patients with advanced renal cell carcinoma

被引：0
|
作者：
Staehler, M. [1 ]
Siebels, M. [2 ]
Stief, C. [1 ]
Jaeger, E.
Heinzer, H.
Grimm, M. -O.
Gschwend, J.
Wirth, M.
Michell, M. -S.
Rohde, D.
Krause, S.
Siegsmund, M.
Scheuring, U.
Schwartz, B.
Escudier, B.
机构：
[1] Univ Munich, Klin Grosshadern Ludwig Maximilians, Munich, Germany
[2] Urol Gemeinschaftspraxis Pasing, Munich, Germany
来源：
ONKOLOGE | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [1] Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    Escudier, B.
    Szczylik, C.
    Eisen, T.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Shan, M.
    Bukowski, R. M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 226
  • [2] Randomised phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 287 - 287
  • [3] Sorafenib (bay 43-9006) in patients with advanced renal cell cancer (MRCC) as second line therapy - Unicentric, results of an multicentric randomised phase III trial of the multi multi-kinase inhibitor
    Staehler, Michael D.
    Haseke, Nicolas
    Schoeppler, Gita M.
    Stadler, Thomas
    Graser, Anno
    Siebels, Michael
    Stief, Christian G.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 166 - 167
  • [4] Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
    Escudier, B
    Szczylik, C
    Eisen, T
    Stadler, WM
    Schwartz, B
    Shan, M
    Bukowski, RM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1093S - 1093S
  • [5] Radiosensitization of human melanoma cells by sorafenib (BAY 43-9006), a multi-kinase inhibitor
    Munshi, Anupama
    Tanaka, Toshimitsu
    Hobbs, Marvette
    Meyn, Raymond E., Jr.
    CANCER RESEARCH, 2006, 66 (08)
  • [6] Kinase inhibition with BAY 43-9006 n renal cell carcinoma
    Ahmad, T
    Eisen, T
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6388S - 6392S
  • [7] Phase II randomised discontinuation study of BAY 43-9006 in patients with advanced melanoma
    Ahmad, T
    Marais, R
    Pyle, L
    James, M
    Schwartz, B
    Gore, M
    Eisen, T
    BRITISH JOURNAL OF CANCER, 2004, 91 : S8 - S8
  • [8] Phase II biomarker analysis of sorafenib (BAY 43-9006) in patients with advanced hepatocellular carcinoma.
    Abou-Alfa, GK
    Schwartz, L
    Ricci, S
    Amadori, D
    Santoro, A
    Figer, A
    De Greve, J
    Douillard, JY
    Taylor, I
    Moscovici, M
    Bigwood, D
    Voliotis, D
    Saltz, LB
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9033S - 9033S
  • [9] Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC)
    Nagaiah, G.
    Fu, P.
    Wasman, J. K.
    Cooney, M. M.
    Mooney, C.
    Afshin, D.
    Lavertu, P.
    Bokar, J.
    Savvides, P.
    Remick, S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma
    Uldrick, Thomas S.
    Goncalves, Priscila H.
    Wyvill, Kathleen M.
    Peer, Cody J.
    Bernstein, Wendy
    Aleman, Karen
    Polizzotto, Mark N.
    Venzon, David
    Steinberg, Seth M.
    Marshall, Vickie
    Whitby, Denise
    Little, Richard F.
    Wright, John J.
    Rudek, Michelle A.
    Figg, William D.
    Yarchoan, Robert
    ONCOLOGIST, 2017, 22 (05): : 505 - +
12345